LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Anatomical characterization of pulmonary artery and implications to pulmonary artery pressure monitor implantation.

    Zafar, Hamza / Neelam-Naganathan, Dharshan / Middleton, Jennifer T / Binmahfooz, Sarah K / Battersby, Christian / Rogers, Dominic / Swift, Andrew J / Rothman, Alexander M K

    Scientific reports

    2023  Volume 13, Issue 1, Page(s) 20528

    Abstract: In patients with heart failure, guideline directed medical therapy improves outcomes and requires close patient monitoring. Pulmonary artery pressure monitors permit remote assessment of cardiopulmonary haemodynamics and facilitate early intervention ... ...

    Abstract In patients with heart failure, guideline directed medical therapy improves outcomes and requires close patient monitoring. Pulmonary artery pressure monitors permit remote assessment of cardiopulmonary haemodynamics and facilitate early intervention that has been shown to decrease heart failure hospitalization. Pressure sensors implanted in the pulmonary vasculature are stabilized through passive or active interaction with the anatomy and communicate with an external reader to relay invasively measured pressure by radiofrequency. A body mass index  > 35 kg/m
    MeSH term(s) Humans ; Pulmonary Artery/diagnostic imaging ; Heart Failure/therapy ; Prostheses and Implants ; Hemodynamics ; Monitoring, Physiologic
    Language English
    Publishing date 2023-11-22
    Publishing country England
    Document type Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-023-47612-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologies.

    Varian, Frances / Dick, Jennifer / Battersby, Christian / Roman, Stefan / Ablott, Jenna / Watson, Lisa / Binmahfooz, Sarah / Zafar, Hamza / Colgan, Gerry / Cannon, John / Suntharalingam, Jay / Lordan, Jim / Howard, Luke / McCabe, Colm / Wort, John / Price, Laura / Church, Colin / Hamilton, Neil / Armstrong, Iain /
    Hameed, Abdul / Hurdman, Judith / Elliot, Charlie / Condliffe, Robin / Wilkins, Martin / Webb, Alastair / Adlam, David / Benza, Ray L / Rahimi, Kazem / Shojaei-Shahrokhabadi, Mohadeseh / Lin, Nan X / Wason, James M S / McIntosh, Alasdair / McConnachie, Alex / Middleton, Jennifer T / Thompson, Roger / Kiely, David G / Toshner, Mark / Rothman, Alexander

    Pulmonary circulation

    2024  Volume 14, Issue 1, Page(s) e12337

    Abstract: Approved therapies for the treatment of patients with pulmonary arterial hypertension (PAH) mediate pulmonary vascular vasodilatation by targeting distinct biological pathways. International guidelines recommend that patients with an inadequate response ... ...

    Abstract Approved therapies for the treatment of patients with pulmonary arterial hypertension (PAH) mediate pulmonary vascular vasodilatation by targeting distinct biological pathways. International guidelines recommend that patients with an inadequate response to dual therapy with a phosphodiesterase type-5 inhibitor (PDE5i) and endothelin receptor antagonist (ERA), are recommended to either intensify oral therapy by adding a selective prostacyclin receptor (IP) agonist (selexipag), or switching from PDE5i to a soluble guanylate-cyclase stimulator (sGCS; riociguat). The clinical equipoise between these therapeutic choices provides the opportunity for evaluation of individualized therapeutic effects. Traditionally, invasive/hospital-based investigations are required to comprehensively assess disease severity and demonstrate treatment benefits. Regulatory-approved, minimally invasive monitors enable equivalent measurements to be obtained while patients are at home. In this 2 × 2 randomized crossover trial, patients with PAH established on guideline-recommended dual therapy and implanted with CardioMEMS™ (a wireless pulmonary artery sensor) and ConfirmRx™ (an insertable cardiac rhythm monitor), will receive ERA + sGCS, or PDEi + ERA + IP agonist. The study will evaluate clinical efficacy via established clinical investigations and remote monitoring technologies, with remote data relayed through regulatory-approved online clinical portals. The primary aim will be the change in right ventricular systolic volume measured by magnetic resonance imaging (MRI) from baseline to maximal tolerated dose with each therapy. Using data from MRI and other outcomes, including hemodynamics, physical activity, physiological measurements, quality of life, and side effect reporting, we will determine whether remote technology facilitates early evaluation of clinical efficacy, and investigate intra-patient efficacy of the two treatment approaches.
    Language English
    Publishing date 2024-03-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2638089-4
    ISSN 2045-8940 ; 2045-8932
    ISSN (online) 2045-8940
    ISSN 2045-8932
    DOI 10.1002/pul2.12337
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top